Ironwood Historical Cash Flow
| IRWD Stock | USD 3.35 0.09 2.62% |
Analysis of Ironwood Pharmaceuticals cash flow over time is an excellent tool to project Ironwood Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 11.8 M or Begin Period Cash Flow of 690.8 M as it is a great indicator of Ironwood Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Ironwood Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ironwood Pharmaceuticals is a good buy for the upcoming year.
Ironwood |
About Ironwood Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Ironwood balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Ironwood's non-liquid assets can be easily converted into cash.
Ironwood Pharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Ironwood Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Ironwood Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Ironwood Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 690.8 M, whereas Stock Based Compensation is forecasted to decline to about 23.8 M.
Ironwood Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Ironwood Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ironwood Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.6M) | 185.5M | 257.1M | 36.1M | (565.8M) | (537.5M) | |
| Stock Based Compensation | 31.3M | 31.2M | 22.3M | 27.0M | 32.0M | 23.8M | |
| Free Cash Flow | 3.5M | 167.0M | 261.6M | 273.6M | 183.2M | 192.3M | |
| Change In Working Capital | (100.0M) | (941K) | 17.7M | 2.8M | 11.3M | 11.8M | |
| Begin Period Cash Flow | 180.8M | 179.2M | 364.8M | 621.9M | 657.9M | 690.8M | |
| Other Cashflows From Financing Activities | 141.6M | 18.5M | 19.6M | 111.2M | (22.8M) | (21.7M) | |
| Depreciation | 5.6M | 3.6M | 1.5M | 1.4M | 1.6M | 1.5M | |
| Other Non Cash Items | 16.4M | 22.3M | 25.2M | 1.7M | 1.1B | 1.1B | |
| Capital Expenditures | 7.2M | 1.8M | 265K | 136K | 273K | 259.4K | |
| Total Cash From Operating Activities | 10.7M | 168.8M | 261.9M | 273.8M | 183.4M | 192.6M | |
| Change To Account Receivables | (68.9M) | 4.1M | 7.7M | 8.0M | 924K | 970.2K | |
| Net Income | 21.5M | 106.2M | 528.4M | 175.1M | (1.0B) | (952.1M) | |
| Total Cash From Financing Activities | (1.2M) | 18.5M | (4.6M) | (237.6M) | 277.2M | 291.0M | |
| End Period Cash Flow | 179.2M | 364.8M | 621.9M | 657.9M | 92.2M | 87.5M | |
| Change To Liabilities | (33.2M) | (7.6M) | 10.1M | (7.9M) | (7.1M) | (7.5M) | |
| Total Cashflows From Investing Activities | (11.1M) | (1.8M) | (265K) | (136K) | (122.4K) | (116.3K) | |
| Sale Purchase Of Stock | 26.4M | 32.1M | 13.6M | 18.5M | (24.1M) | (126.4M) | |
| Investments | (11.1M) | (1.8M) | (265K) | (136K) | (1.0B) | (971.0M) | |
| Change Receivables | (68.9M) | 4.1M | 7.7M | 8.0M | 9.2M | 9.7M | |
| Net Borrowings | 8.5M | (1.8M) | 16.3M | (120.7M) | (108.6M) | (103.2M) | |
| Cash And Cash Equivalents Changes | (1.6M) | 185.5M | 257.1M | 36.1M | 41.5M | 55.6M | |
| Cash Flows Other Operating | (23.9M) | 20.2M | 11.9M | 3.9M | 4.5M | 4.7M | |
| Change To Netincome | 90.0M | 19.5M | (321.7M) | 91.5M | 82.3M | 86.5M | |
| Change To Operating Activities | 725K | 2.7M | 12.7M | 2.9M | 3.4M | 3.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.